Novo Nordisk picks up sickle-cell disease drug in $400M licensing pact; Sapience teams up with UK researcher on cancer drugs
→ Novo Nordisk has been saying that it’s seeking new assets in the hematology space, and today the Danish pharma came up with a licensing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
